BiotechTube
FoRx Therapeutics

FoRx Therapeutics

Basel, Switzerland· Est.
forxtherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $37M

Overview

FoRx Therapeutics is a Swiss clinical-stage biotech focused on a novel oncology approach: targeting DNA Replication Stress. Its lead asset, FORX-428, is a potential best-in-class PARG inhibitor currently in a first-in-human trial, with initial data expected mid-2026. The company is backed by a USD 50M Series A financing round and is led by a team with deep expertise in cancer biology, DNA damage response, and drug development. FoRx aims to address significant unmet need in cancers that develop resistance to current therapies.

Oncology

Technology Platform

Platform for developing small molecule inhibitors targeting key nodes in the DNA Replication Stress and DNA Damage Response pathways to induce synthetic lethality in cancer cells.

Funding History

2
Total raised:$37M
Series A$25M
Seed$12M

Opportunities

Targeting DNA Replication Stress addresses a core vulnerability in many treatment-resistant cancers, a large and growing unmet medical need.
A successful PARG inhibitor could capture share in the multi-billion dollar DDR inhibitor market, particularly in PARP-resistant settings.
The company's Basel location facilitates potential partnerships with major pharmaceutical firms.

Risk Factors

The novel mechanism of action carries inherent clinical risk, with the lead asset's Phase 1 data being a binary near-term catalyst.
As a single-asset, private company, it faces significant financing risk for later-stage development.
It also operates in an emerging but potentially competitive scientific field.

Competitive Landscape

FoRx competes in the DNA Damage Response (DDR) space, which includes established PARP inhibitors (e.g., from AstraZeneca, GSK). Its specific PARG inhibitor approach places it against other biotechs developing PARG inhibitors (e.g., Ideaya Biosciences, others). Its broader 'Replication Stress' platform may face future competition as the biology is further validated.

More companies in Switzerland →